Thermo Fisher To Invest $600 M To Expand Bioprocessing Materials Capacity
Thermo Fisher Scientific has announced more than $600 million in capital investments to expand its bioprocessing materials capacity through 2022 to more than double the company’s current manufacturing capacity.
Specific investments include expansions in: (1) single-use technologies; (2) purification resins; and (3) cell-culture media and process liquids. With these investments, the company expects to create more than 1,500 new jobs across 11 manufacturing sites in the Americas, Europe, and Asia.
Single-use technologies expansions
Thermo Fisher’s single-use technologies business is expanding capacity at sites at the following site: Logan, Utah; Millersburg, Pennsylvania.; Cramlington, UK; Singapore; and Suzhou, China. Additional investment at the company’s Santa Clara, California site will expand bioprocessing equipment and automation capacity.
Expansions for purification resins
The company will also expand its POROS resin manufacturing site in Bedford, Massachusetts and open a new 85,000-square-foot manufacturing facility in Chelmsford, Massachusetts. Thermo Fisher’s purification network specializes in the production of process-scale chromatography resins for a variety of applications, including vaccines and gene therapies.
Cell-culture media and process liquid expansions
The company plans to expand capacity for its Gibco cell-culture media, supplements, and process liquids as well as the manufacturing of customer-owned proprietary media formulations at the following sites: Grand Island, New York; Miami, Florida; and Inchinnan, Scotland.
Source: Thermo Fisher Scientific